Neutrophil-to-lymphocyte ratio is an independent risk factor for proteinuria non-remission in idiopathic membranous nephropathy
(Source: International Urology and Nephrology)
Source: International Urology and Nephrology - April 9, 2024 Category: Urology & Nephrology Source Type: research
Nephronophthisis 13 caused by WDR19 variants with pancytopenia: case report
We present a case of nephronophthisis 13 that resulted fromWDR19 variants. The patient, a nine-year-old Japanese boy, had detection of mild proteinuria during a school urine screening. Urinalysis revealed mild proteinuria without hematuria. Blood tests indicated pancytopenia, mild elevation of liver enzymes, and kidney dysfunction. Ultrasound examination disclosed hepatosplenomegaly. Abdominal computed tomography and bone marrow assessments ruled out malignant tumors. Subsequent kidney and liver biopsies suggested nephronophthisis and congenital hepatic fibrosis. Furthermore, comprehensive genetic analysis through next-gen...
Source: CEN Case Reports - April 8, 2024 Category: Urology & Nephrology Source Type: research
Clinicopathological characteristics and gene mutations in 11 patients with lipoprotein glomerulopathy
CONCLUSION: LPG is histologically characterized by lamellated lipoprotein thrombi in glomeruli, and kidney biopsy is essential for diagnosis. Mutations in the APOE gene are the leading cause of LPG. This study revealed clinicopathological characteristics and APOE gene mutations in patients with LPG, which helps us better understand the disease.PMID:38584145 | DOI:10.1080/0886022X.2024.2332491 (Source: Renal Failure)
Source: Renal Failure - April 7, 2024 Category: Urology & Nephrology Authors: Yan Qin Xiao-Jing Sun Yi-Fang Hu Meng Jing Xiao-Juan Yu Ming-Hui Zhao Ying Tan Source Type: research
Clinicopathological characteristics and gene mutations in 11 patients with lipoprotein glomerulopathy
CONCLUSION: LPG is histologically characterized by lamellated lipoprotein thrombi in glomeruli, and kidney biopsy is essential for diagnosis. Mutations in the APOE gene are the leading cause of LPG. This study revealed clinicopathological characteristics and APOE gene mutations in patients with LPG, which helps us better understand the disease.PMID:38584145 | PMC:PMC10967672 | DOI:10.1080/0886022X.2024.2332491 (Source: Renal Failure)
Source: Renal Failure - April 7, 2024 Category: Urology & Nephrology Authors: Yan Qin Xiao-Jing Sun Yi-Fang Hu Meng Jing Xiao-Juan Yu Ming-Hui Zhao Ying Tan Source Type: research
Cigarette smoking and progression of kidney dysfunction: a longitudinal cohort study
ConclusionLarge longitudinal observation study revealed smoking has an evil effect on the progression of CKD. This evil effect could be observed in CKD patients with proteinuria as well as in general population without new-onset proteinuria. (Source: Clinical and Experimental Nephrology)
Source: Clinical and Experimental Nephrology - April 6, 2024 Category: Urology & Nephrology Source Type: research
Tolvaptan therapy for edema in patients with chronic kidney disease
CONCLUSION: As long as a rational treatment regimen is followed, tolvaptan is a safe and effective diuretic for treating edema in CKD, even in the late stages of CKD without reducing residual renal function in the patients.PMID:38577748 | DOI:10.5414/CN111365 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 5, 2024 Category: Urology & Nephrology Authors: Li Zhou Qianqian Xu Xuehua Xi Xueying Yu Wenge Li Source Type: research
Toll like receptor 4 mediates the inhibitory effect of SARS-CoV-2 spike protein on proximal tubule albumin endocytosis
Biochim Biophys Acta Mol Basis Dis. 2024 Apr 3:167155. doi: 10.1016/j.bbadis.2024.167155. Online ahead of print.ABSTRACTTubular proteinuria is a common feature in COVID-19 patients, even in the absence of established acute kidney injury. SARS-CoV-2 spike protein (S protein) was shown to inhibit megalin-mediated albumin endocytosis in proximal tubule epithelial cells (PTECs). Angiotensin-converting enzyme type 2 (ACE2) was not directly involved. Since Toll-like receptor 4 (TLR4) mediates S protein effects in various cell types, we hypothesized that TLR4 could be participating in the inhibition of PTECs albumin endocytosis e...
Source: Biochimica et Biophysica Acta - April 5, 2024 Category: Biochemistry Authors: Rodrigo P Silva-Aguiar Douglas E Teixeira Diogo B Peruchetti Rodrigo A S Peres Sarah A S Alves Pedro T Calil Luciana B Arruda Luciana J Costa Pedro L Silva Alvin H Schmaier Patricia R M Rocco Ana Acacia S Pinheiro Celso Caruso-Neves Source Type: research
Tolvaptan therapy for edema in patients with chronic kidney disease
CONCLUSION: As long as a rational treatment regimen is followed, tolvaptan is a safe and effective diuretic for treating edema in CKD, even in the late stages of CKD without reducing residual renal function in the patients.PMID:38577748 | DOI:10.5414/CN111365 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 5, 2024 Category: Urology & Nephrology Authors: Li Zhou Qianqian Xu Xuehua Xi Xueying Yu Wenge Li Source Type: research
Toll like receptor 4 mediates the inhibitory effect of SARS-CoV-2 spike protein on proximal tubule albumin endocytosis
Biochim Biophys Acta Mol Basis Dis. 2024 Apr 3:167155. doi: 10.1016/j.bbadis.2024.167155. Online ahead of print.ABSTRACTTubular proteinuria is a common feature in COVID-19 patients, even in the absence of established acute kidney injury. SARS-CoV-2 spike protein (S protein) was shown to inhibit megalin-mediated albumin endocytosis in proximal tubule epithelial cells (PTECs). Angiotensin-converting enzyme type 2 (ACE2) was not directly involved. Since Toll-like receptor 4 (TLR4) mediates S protein effects in various cell types, we hypothesized that TLR4 could be participating in the inhibition of PTECs albumin endocytosis e...
Source: Biochimica et Biophysica Acta - April 5, 2024 Category: Biochemistry Authors: Rodrigo P Silva-Aguiar Douglas E Teixeira Diogo B Peruchetti Rodrigo A S Peres Sarah A S Alves Pedro T Calil Luciana B Arruda Luciana J Costa Pedro L Silva Alvin H Schmaier Patricia R M Rocco Ana Acacia S Pinheiro Celso Caruso-Neves Source Type: research
Tolvaptan therapy for edema in patients with chronic kidney disease
CONCLUSION: As long as a rational treatment regimen is followed, tolvaptan is a safe and effective diuretic for treating edema in CKD, even in the late stages of CKD without reducing residual renal function in the patients.PMID:38577748 | DOI:10.5414/CN111365 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 5, 2024 Category: Urology & Nephrology Authors: Li Zhou Qianqian Xu Xuehua Xi Xueying Yu Wenge Li Source Type: research
Tolvaptan therapy for edema in patients with chronic kidney disease
CONCLUSION: As long as a rational treatment regimen is followed, tolvaptan is a safe and effective diuretic for treating edema in CKD, even in the late stages of CKD without reducing residual renal function in the patients.PMID:38577748 | DOI:10.5414/CN111365 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 5, 2024 Category: Urology & Nephrology Authors: Li Zhou Qianqian Xu Xuehua Xi Xueying Yu Wenge Li Source Type: research
Tolvaptan therapy for edema in patients with chronic kidney disease
CONCLUSION: As long as a rational treatment regimen is followed, tolvaptan is a safe and effective diuretic for treating edema in CKD, even in the late stages of CKD without reducing residual renal function in the patients.PMID:38577748 | DOI:10.5414/CN111365 (Source: Clinical Nephrology)
Source: Clinical Nephrology - April 5, 2024 Category: Urology & Nephrology Authors: Li Zhou Qianqian Xu Xuehua Xi Xueying Yu Wenge Li Source Type: research
